Detail of "53-42-9"

Reference

Comparative effect of three long-acting steroidal contraceptives on total and fractional urinary 17-oxosteroids in rats

Comparative effect of three long-acting steroidal contraceptives on total and fractional urinary 17-oxosteroids in rats. Abdel-Kader, M. M.; Galal, E. E.; Idris, Amal; Badawi, M. M.; Madkour, M. K. (Natl. Organ. Drug Res. Control, Cairo, Egypt). J. Drug Res., 14(1-2), 133-40 (English) 1983. CODEN: JDGRAX. ISSN: 0368-1866. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Female rats were treated with medroxyprogesterone acetate (MPA) [71-58-9] (0.0158 mg/100 g, i.m.), Quinestrol (QNST) [152-43-2] (0.05 mg/100 g, by oral gavage), or Deladroxate (DDXT) [8055-16-1] (1.5 mg/100 g, i.m.), after which the urinary 17-oxo steroids, including dehydroepiandrosterone (DHEA) [53-43-0], androsterone (ADS) [53-41-8], and etiocholanolone [53-42-9] were detd. Vaginal smear cytol. of MPA-treated rats showed a persistent estrous pattern in 20% of the rats on the 50th day after treatment. Since MPA showed only a weak estrogenic action, it may cause this persistent estrous pattern by acting directly on the vaginal epithelium. In contrast, QNST caused a pure diestrous pattern in the vaginal smear at 15 days in 100% of the rats; this decreased to 75% on the 75th and 135th days of observation. The long-term effect of QNST on ovulation results from its slow release from fat depots in which it is stored. DDXT caused a heterogenous vaginal smear pattern related to the ovulation-inhibiting effects of the progestogen it contains. MPA initially decreased the urinary excretion levels of the 3 oxo steroids, probably because of its inhibition of ovarian steroidogenesis. The DHEA and ADS urinary excretion levels were, however, elevated at the 50th day, the increases disappearing at 100 days. QNST had a variety of heterogenous effects on the urinary 17-oxo steroids; its estrogenic effect may be due to an increase of sulfate conjugation.

Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen

Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen. Coleman, Douglas L.; Applezweig, Norman (Progenics, Inc.; Jackson Laboratory, USA). U.S. US 4507289 A 26 Mar 1985, 5 pp. (English). (United States of America). CODEN: USXXAM. CLASS: ICM: A61K031-56. NCL: 514170000. APPLICATION: US 83-566222 28 Dec 1983. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Diabetes and assocd. hypercorticoidism were treated with the synergistic combination of a-etiocholanolone (I) [53-42-9] and(or) b-etiocholanolone (II) [571-31-3] and an estrogen. Thus, estradiol [50-28-2] (50 mg injected twice), I (0.1% diet), and II (0.1% diet) were effective in preventing the development of severe diabetes in diabetes-mutant mice. Pharmacol. formulations for the therapy were described. E.g., capsules will contain I 50, estradiol 0.04, lactose 50, di-Ca phosphate 50, Mg stearate 2, and talc 10 mg.